Effects of Nutritional, Endocrine and Metabolic State on the Development of Intravascular Coagulation Induced by Human Serum Preparations with Procoagulant Activity

Harry N. Antoniades; Panayotis G. Iatridis; Nelson Westmoreland; James D. Simon; Kenneth C. Hayes; Douglas MacN. Surgenor

doi:10.1055/s-0038-1647744

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 1973; 29(01): 033-049
DOI: 10.1055/s-0038-1647744

Original Article

Schattauer GmbH

Effects of Nutritional, Endocrine and Metabolic State on the Development of Intravascular Coagulation Induced by Human Serum Preparations with Procoagulant Activity

Harry N. Antoniades

¹Center for Blood Research and the Department of Nutrition, Harvard University, School of Public Health, Boston, Massachusetts, the Department of Physiology, Medical School, University of North Carolina, Chapel Hill, North Carolina, the Department of Biochemistry, State University of New York at Buffalo, Buffalo, New York

,

Panayotis G. Iatridis

¹Center for Blood Research and the Department of Nutrition, Harvard University, School of Public Health, Boston, Massachusetts, the Department of Physiology, Medical School, University of North Carolina, Chapel Hill, North Carolina, the Department of Biochemistry, State University of New York at Buffalo, Buffalo, New York

,

Nelson Westmoreland

¹Center for Blood Research and the Department of Nutrition, Harvard University, School of Public Health, Boston, Massachusetts, the Department of Physiology, Medical School, University of North Carolina, Chapel Hill, North Carolina, the Department of Biochemistry, State University of New York at Buffalo, Buffalo, New York

,

James D. Simon

¹Center for Blood Research and the Department of Nutrition, Harvard University, School of Public Health, Boston, Massachusetts, the Department of Physiology, Medical School, University of North Carolina, Chapel Hill, North Carolina, the Department of Biochemistry, State University of New York at Buffalo, Buffalo, New York

,

Kenneth C. Hayes

¹Center for Blood Research and the Department of Nutrition, Harvard University, School of Public Health, Boston, Massachusetts, the Department of Physiology, Medical School, University of North Carolina, Chapel Hill, North Carolina, the Department of Biochemistry, State University of New York at Buffalo, Buffalo, New York

,

Douglas MacN. Surgenor

¹Center for Blood Research and the Department of Nutrition, Harvard University, School of Public Health, Boston, Massachusetts, the Department of Physiology, Medical School, University of North Carolina, Chapel Hill, North Carolina, the Department of Biochemistry, State University of New York at Buffalo, Buffalo, New York

› Institutsangaben

Abstract

Summary

Injection of human serum fractions with procoagulant activity into intact rats initiated hypercoagulability, thrombosis and hemorrhage. These in vivo effects were dependent upon the nutritional, endocrine and metabolic state of the animals. Injection in fed rats produced only transient hypercoagulability. In rats fasted 48 hours, the initial hypercoagulability was followed by prolonged hypocoagulation, a decline in blood platelet count, thrombosis and hemorrhage. These effects were reversed in fasted rats by glucose injected 1 hour before the serum fractions. Alloxan-diabetic fed rats and genetically obese fed rats also exhibited enhanced susceptibility to intravascular coagulation on injection of the serum fraction. However, injection of insulin in the diabetic rats before the serum fractions greatly reduced the susceptibility of these animals. The serum fractions used in these studies exhibited potent factor XIIa-like activity in vitro. The present studies demonstrate that the in vivo clotting process can be greatly influenced by the nutritional, endocrine, and metabolic state of the animal and they provide a basis for the investigation of the factors involved.

Volltext

Referenzen

References
1 Antoniades H. N, Iatridis P. G, Gershoff S. N, Sweeney E. A. 1969; Thrombohemorrhagic effects in fasted rats produced by the injection of partially purified human serum concentrates. Vox Sanguinis 17: 66.
2 Bowie E JW, Thompson Jr. J. H., Didisheim P, Owen Jr. C. A.. 1971. Mayo Clinic, Laboratory Manual of Hemostasis. W. B. Saunders Company; Philadelphia.:
3 Barton P. G, Yin E. T, Wessler S. 1970; Reactions of activated Factor X-phosphatide mixtures in vitro and in vivo. Journal of Lipid Research 11: 87.
4 Cannon W. B, Gray H. 1914; Factors affecting the coagulation time of blood. II. The hastening or retarding of coagulation by adrenalin injections. American Journal of Physiology 54: 232.
5 Carpenter K. J, Gotsis A, Hegsted D. M. 1957; Estimation of total cholesterol in serum by a micromethod. Clinical Chemistry 03: 233.
6 Connor W. E, Hoak J. C, Warner E. D. 1963; Massive thrombosis produced by fatty acid infusion. Journal of Clinical Investigation 42: 860.
7 Connor W. E, Hoak J. C, Warner E. D. 1966; The role of lipids in thrombosis. Thrombosis et Diathes Haemorrhagica, Supplement 21: 193.
8 Connor W. E, Hoak J. C, Warner E. D. 1969. Plasma free fatty acids, hypercoagulability and thrombosis. In: Sherry S, Brinkhous K. M, Glenton E, Stengle J. M. (eds.), Thrombosis. National Academy of Science; Washington, D. C: 355.
9 Didisheim P, Vendervooret R LE, Rutting J. E. 1962; Formation of serum thrombotic accelerator (STA) in plasma. Clinical Research 10: 77.
10 Dole V. P. 1956; A relation between non-esterified fatty acids in plasma and the metabolites of glucose. Journal of Clinical Investigation 35: 150.
11 Feissly R. 1925; La stabilite du fibrinogene in vivo. Comptes Rendus des Seances de la Societe de Biologie 92: 319.
12 Hayem G. 1923. L’Hematoblast. Les Presses Universitaires de France; Paris.:
13 Henderson E. S, Rapaport S. I. 1962; The thrombotic activity of the activation product. Journal of Clinical Investigation 41: 235.
14 Hicks N. D, Pitney W. R. 1957; A rapid screening test for disorders of thromboplastin generation. British Journal of Haematology 03: 227.
15 Hoak J. C. 1964; Structure of thrombi produced by injection of fatty acids. British Journal of Experimental Pathology 45: 44.
16 Hoak J. C, Robinson D. S. 1963; Thrombosis associated with mobilization of fatty acids. American Journal of Pathology 43: 987.
17 Hoffman W. S. 1937; A rapid photoelectric method for the determination of glucose in blood and urine. Journal of Biological Chemistry 120: 51.
18 Iatridis S. G, Ferguson J. H. 1962; A two stage assay method for Hageman factor activity. Thrombosis et Diathesis Haemorrhagica 08: 46.
19 Iatridis S. G, Ferguson J. H, Iatridis P. G, Mauldin R. 1964; a): Thrombogenic properties of surface factor: Evidence for an antisurface factor in canine plasma. Thrombosis et Diathesis Haemorrhagica 12: 35.
20 Iatridis S. G, Iatridis P. G, Ferguson J. G. 1964; b Roles of surface factor and plasma inhibitory activity (anti-SFO) during experimental thrombosis in rabbits. Thrombosis et Diathesis Haemorrhagica 12: 489.
21 Lowry O. H, Rosebrough N. J, Farr A. L, Randall R. J. 1951; Protein measurement with the Folin phenol reagent. Journal of Biological Chemistry 193: 265.
22 McKay D. G, Latour J. G, Lopez A. M. 1971; Production of the generalized Shwartzman reaction by activated Hageman Factor and α-adrenergic stimulation. Thrombosis et Diathesis Haemorrhagica 26: 71.
23 Mammen E. F, Grammens G. K. 1967; a: Purification and properties of bovine Hageman factor. Federation Proceedings 26: 760.
24 Mammen E. F, Grammens G. L. 1967; b The purification and some properties of bovine Hageman factor. Thrombosis et Diathesis Haemorrhagica 18: 306.
25 Moore J. H. 1962; A modified method for the determination of glyceride glycerol. Journal of Dairy Research 29: 141.
26 Quick A. J, Stanley-Borwn M, Bancroft F. W. 1935; A study of the coagulation defect in hemophilia and in jaundice. The American Journal of the Medical Sciences 190: 501.
27 Ratnoff O. D, Menzie C. 1951; A new method for the determination of fibrinogen in small samples of plasma. Journal of Laboratoiry and Clinical Medicine 37: 316.
28 Seegers W. H, Smith H. P. 1942; Factors which influence the activity of purified thrombin. American Journal of Physiology 137: 348.
29 Sweeney E. A, Gershoff S. N, Antoniades H. N. 1966; Observations on the in vitro and in vivo agglutination of platelets by “bound” insulin concentrates. Proceedings of the Society for Experimental Biology and Medicine 121: 880.
30 Wessler S. 1955; Studies in intravascular coagulation. III. The pathogenesis of serum-induced venous thrombosis. Journal of Clinical Investigation 34: 647.
31 Wessler S. 1962; Thrombosis in the presence of vascular stasis. American Journal of Medicine 33: 648.
32 Wessler S, Yin E. T. 1968; Experimental hypercoagulable state induced by Factor X: Comparison of the nonacivated and activated forms. Journal of Laboratory and Clinical Medicine 72: 256.
33 Wessler S, Reimer S. M. 1960; The role of human coagulation factors in serum-induced thrombosis. Journal of Clinical Investigation 39: 262.
34 Zbinden G. 1964; Transient thrombopenia after intravenous injection of certain fatty acids. Journal of Lipid Research 05: 378.
35 Zucker L. M. 1965; Hereditary obesity in rats associated with hyperlipemia. Annals of the New York Academy of Sciences 131: 447.
36 Zucker L. M, Antoniades H. N. 1972; Insulin and obesity in the Zucker genetically obese rat “fatty”. Endocrinology 90: 1320.
37 Zucker T. F, Zucker L. M. 1962; Hereditary obesity in the rat associated with high serum fat and cholesterol. Proceedings of the Society for Experimental biology and Medicine 110: 165.